mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States

Hung Fu Tseng (), Bradley K. Ackerson, Lina S. Sy, Julia E. Tubert, Yi Luo, Sijia Qiu, Gina S. Lee, Katia J. Bruxvoort, Jennifer H. Ku, Ana Florea, Harpreet S. Takhar, Radha Bathala, Cindy Ke Zhou, Daina B. Esposito, Morgan A. Marks, Evan J. Anderson, Carla A. Talarico and Lei Qian
Additional contact information
Hung Fu Tseng: Kaiser Permanente Southern California
Bradley K. Ackerson: Kaiser Permanente Southern California
Lina S. Sy: Kaiser Permanente Southern California
Julia E. Tubert: Kaiser Permanente Southern California
Yi Luo: Kaiser Permanente Southern California
Sijia Qiu: Kaiser Permanente Southern California
Gina S. Lee: Kaiser Permanente Southern California
Katia J. Bruxvoort: Kaiser Permanente Southern California
Jennifer H. Ku: Kaiser Permanente Southern California
Ana Florea: Kaiser Permanente Southern California
Harpreet S. Takhar: Kaiser Permanente Southern California
Radha Bathala: Kaiser Permanente Southern California
Cindy Ke Zhou: Moderna Inc.
Daina B. Esposito: Moderna Inc.
Morgan A. Marks: Moderna Inc.
Evan J. Anderson: Moderna Inc.
Carla A. Talarico: Moderna Inc.
Lei Qian: Kaiser Permanente Southern California

Nature Communications, 2023, vol. 14, issue 1, 1-11

Abstract: Abstract The bivalent (original and Omicron BA.4/BA.5) mRNA-1273 COVID-19 vaccine was authorized to offer broader protection against COVID-19. We conducted a matched cohort study to evaluate the effectiveness of the bivalent vaccine in preventing hospitalization for COVID-19 (primary outcome) and medically attended SARS-CoV-2 infection and hospital death (secondary outcomes). Compared to individuals who did not receive bivalent mRNA vaccination but received ≥2 doses of any monovalent mRNA vaccine, the relative vaccine effectiveness (rVE) against hospitalization for COVID-19 was 70.3% (95% confidence interval, 64.0%–75.4%). rVE was consistent across subgroups and not modified by time since last monovalent dose or number of monovalent doses received. Protection was durable ≥3 months after the bivalent booster. rVE against SARS-CoV-2 infection requiring emergency department/urgent care and against COVID-19 hospital death was 55.0% (50.8%–58.8%) and 82.7% (63.7%–91.7%), respectively. The mRNA-1273 bivalent booster provides additional protection against hospitalization for COVID-19, medically attended SARS-CoV-2 infection, and COVID-19 hospital death.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-41537-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-41537-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-41537-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().